{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:15:02Z","timestamp":1777439702486,"version":"3.51.4"},"reference-count":289,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bcp.2020.114057","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T20:40:40Z","timestamp":1590525640000},"page":"114057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost"],"prefix":"10.1016","volume":"178","author":[{"given":"Manar","family":"Mohammed El Tabaa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maram","family":"Mohammed El Tabaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.114057_b0005","doi-asserted-by":"crossref","unstructured":"C. Lai, Y.H. Liu, C. Wang, Y. Wang, S. Hsueh, M. Yen, W. Ko, P.R. Hsueh, Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths, J. Microbiol. Immunol. Infect. (2020).","DOI":"10.1016\/j.jmii.2020.02.012"},{"key":"10.1016\/j.bcp.2020.114057_b0010","unstructured":"M. Cascella, M. Rajnik, A. Cuomo, S.C. Dulebohn, R. Di Napoli, Features, evaluation and treatment coronavirus (COVID-19), in: StatPearls, 2020."},{"issue":"2020","key":"10.1016\/j.bcp.2020.114057_b0015","first-page":"497","article-title":"Clinical features of patients infected with, novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.bcp.2020.114057_b0020","doi-asserted-by":"crossref","first-page":"m641","DOI":"10.1136\/bmj.m641","article-title":"Coronavirus: covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate","volume":"368","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.bcp.2020.114057_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMc2009226","article-title":"Clinical characteristics of Covid-19 in China","volume":"382","author":"Chen","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.114057_b0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1473-3099(20)30086-4","article-title":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study","volume":"20","author":"Shi","year":"2020","journal-title":"Lancet. Infect. Dis."},{"key":"10.1016\/j.bcp.2020.114057_b0035","doi-asserted-by":"crossref","first-page":"66","DOI":"10.15698\/cst2020.04.216","article-title":"Coronavirus infections: epidemiological, clinical and immunological features and hypotheses","volume":"4","author":"Raoult","year":"2020","journal-title":"Cell Stress."},{"key":"10.1016\/j.bcp.2020.114057_b0040","doi-asserted-by":"crossref","unstructured":"A.F. Rabi, S.M. Al Zoubi, A.G. Kasasbeh, M.D. Salameh, D.A. Al-Nasser, SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far, Pathogens. 9 (2020).","DOI":"10.3390\/pathogens9030231"},{"key":"10.1016\/j.bcp.2020.114057_b0045","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2020.114057_b0050","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2020.114057_b0055","first-page":"2019","article-title":"Correspondence Use of antiviral drugs to reduce COVID-19","author":"Mitj\u00e0","year":"2020","journal-title":"Lancet Glob. Heal."},{"key":"10.1016\/j.bcp.2020.114057_b0060","doi-asserted-by":"crossref","unstructured":"G. Li, E. De Clercq, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat. Rev. Drug Discov. 19 (2020) 149\u2013150.","DOI":"10.1038\/d41573-020-00016-0"},{"key":"10.1016\/j.bcp.2020.114057_b0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","author":"Lu","year":"2020","journal-title":"Biosci. Trends."},{"key":"10.1016\/j.bcp.2020.114057_b0070","doi-asserted-by":"crossref","unstructured":"X. Li, M. Geng, Y. Peng, L. Meng, S. Lu, Molecular immune pathogenesis and diagnosis of COVID-19, J. Pharm. Anal. (2020).","DOI":"10.1016\/j.jpha.2020.03.001"},{"key":"10.1016\/j.bcp.2020.114057_b0075","doi-asserted-by":"crossref","unstructured":"K. Tveito, Cytokinstormer ved covid-19?, Tidsskr. Den Nor. Legeforening. (2020).","DOI":"10.4045\/tidsskr.20.0239"},{"key":"10.1016\/j.bcp.2020.114057_b0080","doi-asserted-by":"crossref","unstructured":"G. Zhang, C. Hu, L. Luo, F. Fang, Y. Chen, J. Li, Z. Peng, H. Pan, Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China, MedRxiv. (2020).","DOI":"10.1101\/2020.03.02.20030452"},{"key":"10.1016\/j.bcp.2020.114057_b0085","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV- 2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J. Biol. Regul. Homeost. Agents."},{"key":"10.1016\/j.bcp.2020.114057_b0090","doi-asserted-by":"crossref","unstructured":"D.E. Leisman, C.S. Deutschman, M. Legrand, Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation, Intensive Care Med. (2020) 1\u20134.","DOI":"10.1007\/s00134-020-06059-6"},{"key":"10.1016\/j.bcp.2020.114057_b0095","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/thoraxjnl-2015-207461","article-title":"The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities","volume":"71","author":"Millar","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.bcp.2020.114057_b0100","article-title":"Brain, behavior, and immunity COVID-19 presenting as stroke","volume":"1","author":"Avula","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bcp.2020.114057_b0105","article-title":"Comparative study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting uncontrolled inflammation might not be the main reason of tissue injury","author":"Zheng","year":"2020","journal-title":"MedRxiv."},{"key":"10.1016\/j.bcp.2020.114057_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bcp.2020.114057_b0115","unstructured":"Rong Qu, Yun Ling, Yi\u2010huizhi Zhang, Li\u2010ya Wei, Xiao Chen, Xumian Li, Xuan\u2010yong Liu, Han\u2010mian Liu, Zhi Guo, Hua Ren, Qiang Wang, Platelet-to-lymphocyte ratio is associated with prognosis in patients with Corona Virus Disease-19, J. Med. Virol. (2020) 0\u20133."},{"key":"10.1016\/j.bcp.2020.114057_b0120","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3332\/ecancer.2020.1022","article-title":"Associations between immune-suppressive and stimulating drugs and novel COVID-19\u2014a systematic review of current evidence","volume":"14","author":"Russell","year":"2020","journal-title":"Ecancermedicalscience."},{"key":"10.1016\/j.bcp.2020.114057_b0125","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today\u2019s diseases","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bcp.2020.114057_b0130","unstructured":"P. Smith, T. BCPS, P. Tony Prosser, COVID-19 drug therapy-potential options, Clin. Drug Information, Clin. Solut. March (2020)."},{"key":"10.1016\/j.bcp.2020.114057_b0135","doi-asserted-by":"crossref","unstructured":"J. Sun, W.-T. He, L. Wang, A. Lai, X. Ji, X. Zhai, G. Li, M.A. Suchard, J. Tian, J. Zhou, M. Veit, S. Su, COVID-19: epidemiology, evolution, and cross-disciplinary perspectives, Trends Mol. Med. (2020).","DOI":"10.1016\/j.molmed.2020.02.008"},{"key":"10.1016\/j.bcp.2020.114057_b0140","doi-asserted-by":"crossref","unstructured":"L. Malha, F.B. Mueller, M.S. Pecker, S.J. Mann, P. August, P.U. Feig, COVID-19 and the Renin-Angiotensin System, Kidney Int. Reports. (2020).","DOI":"10.1016\/j.ekir.2020.03.024"},{"key":"10.1016\/j.bcp.2020.114057_b0145","doi-asserted-by":"crossref","unstructured":"G.M. Kuster, O. Pfister, T. Burkard, Q. Zhou, R. Twerenbold, P. Haaf, A.F. Widmer, S. Osswald, SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?, Eur. Heart J. (2020) 1\u20133.","DOI":"10.1093\/eurheartj\/ehaa235"},{"key":"10.1016\/j.bcp.2020.114057_b0150","article-title":"Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome Coronavirus 2 infec","volume":"9","author":"Junyi","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.bcp.2020.114057_b0155","doi-asserted-by":"crossref","unstructured":"M. Vaduganathan, O. Vardeny, T. Michel, J.J. V McMurray, M.A. Pfeffer, S.D. Solomon, Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19, N. Engl. J. Med. (2020).","DOI":"10.1056\/NEJMsr2005760"},{"key":"10.1016\/j.bcp.2020.114057_b0160","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","article-title":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?","volume":"38","author":"Esler","year":"2020","journal-title":"J. Hypertens."},{"key":"10.1016\/j.bcp.2020.114057_b0165","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2337\/db16-1318","article-title":"Neprilysin is required for angiotensin-(1\u20137)\u2019s ability to enhance insulin secretion via its proteolytic activity to generate angiotensin-(1\u20132)","volume":"66","author":"Brar","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2020.114057_b0170","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00125-019-4889-y","article-title":"Neprilysin inhibition: a new therapeutic option for type 2 diabetes?","volume":"62","author":"Esser","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2020.114057_b0175","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1093\/cvr\/cvz223","article-title":"PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction","volume":"115","author":"Docherty","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2020.114057_b0180","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1111\/bph.12694","article-title":"Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis","volume":"171","author":"Baliga","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114057_b0185","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1465-9921-11-164","article-title":"Expression of neutral endopeptidase activity during clinical and experimental acute lung injury","volume":"11","author":"Hashimoto","year":"2010","journal-title":"Respir. Res."},{"key":"10.1016\/j.bcp.2020.114057_b0190","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1164\/rccm.201002-0154OC","article-title":"Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease","volume":"183","author":"Wick","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bcp.2020.114057_b0195","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1152\/jappl.1989.66.6.2653","article-title":"Neutral endopeptidase and neurogenic inflammation in rats with respiratory infections","volume":"66","author":"Borson","year":"1989","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.bcp.2020.114057_b0200","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, function, and evolution of coronavirus spike proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.bcp.2020.114057_b0205","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/pathogens9030186","article-title":"Insights into the recent 2019 novel Coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks","volume":"9","author":"Ashour","year":"2020","journal-title":"Pathogens."},{"key":"10.1016\/j.bcp.2020.114057_b0210","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature17200","article-title":"Pre-fusion structure of a human coronavirus spike protein","volume":"531","author":"Kirchdoerfer","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.114057_b0215","doi-asserted-by":"crossref","unstructured":"C. Yin, Genotyping coronavirus SARS-CoV-2: methods and implications, ArXiv Prepr. ArXiv2003.10965 (2020).","DOI":"10.1016\/j.ygeno.2020.04.016"},{"key":"10.1016\/j.bcp.2020.114057_b0220","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/jiy018","article-title":"Receptor usage of a novel bat lineage c betacoronavirus reveals evolution of Middle East respiratory syndrome-related coronavirus spike proteins for human dipeptidyl peptidase 4 binding","volume":"218","author":"Lau","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bcp.2020.114057_b0225","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcp.2020.114057_b0230","article-title":"Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity","author":"Zhu","year":"2020","journal-title":"BioRxiv."},{"key":"10.1016\/j.bcp.2020.114057_b0235","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1128\/JVI.01542-10","article-title":"Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2","volume":"84","author":"Matsuyama","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2020.114057_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2020.114057_b0245","doi-asserted-by":"crossref","unstructured":"X. Ou, Y. Liu, X. Lei, P. Li, D. Mi, L. Ren, L. Guo, R. Guo, T. Chen, J. Hu, Z. Xiang, Z. Mu, X. Chen, J. Chen, K. Hu, Q. Jin, J. Wang, Z. Qian, Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV, Nat. Commun. (2020).","DOI":"10.1038\/s41467-020-15562-9"},{"key":"10.1016\/j.bcp.2020.114057_b0250","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.jhh.1001960","article-title":"RAS inhibition in hypertension","volume":"20","author":"Ibrahim","year":"2006","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.bcp.2020.114057_b0255","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.acvd.2012.02.010","article-title":"Three key proteases\u2013angiotensin-I-converting enzyme (ACE), ACE2 and renin\u2013within and beyond the renin-angiotensin system","volume":"105","author":"Guang","year":"2012","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.bcp.2020.114057_b0260","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2174\/1381612033455431","article-title":"The pulmonary renin-angiotensin system","volume":"9","author":"Marshall","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2020.114057_b0265","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1159\/000430131","article-title":"Angiotensin-converting enzyme 2 attenuates bleomycin-induced lung fibrosis in mice","volume":"36","author":"Wang","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bcp.2020.114057_b0270","doi-asserted-by":"crossref","unstructured":"G.S. Magalh\u00e3es, M.J. Campagnole-Santos, M. da Gl\u00f3ria Rodrigues-Machado, Lung BT - Angiotensin-(1-7): A Comprehensive Review, in: R.A.S. Santos (Ed.), Cham, 2019, pp. 131\u2013152.","DOI":"10.1007\/978-3-030-22696-1_9"},{"key":"10.1016\/j.bcp.2020.114057_b0275","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1113\/expphysiol.2007.040048","article-title":"The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice","volume":"93","author":"Imai","year":"2008","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.bcp.2020.114057_b0280","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.coph.2006.03.001","article-title":"Angiotensin-converting enzyme 2 in lung diseases","volume":"6","author":"Kuba","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114057_b0285","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fendo.2014.00113","article-title":"Clinical relevance of local renin angiotensin systems","volume":"5","author":"Campbell","year":"2014","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"10.1016\/j.bcp.2020.114057_b0290","doi-asserted-by":"crossref","first-page":"19840","DOI":"10.1038\/srep19840","article-title":"Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus","volume":"6","author":"Gu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2020.114057_b0295","unstructured":"A.C. Guyton, Textbook Of Medical Physiology, 2016."},{"key":"10.1016\/j.bcp.2020.114057_b0300","unstructured":"B. Greenberg, An ACE in the hole: alternative pathways of the renin angiotensin system and their potential role in cardiac remodeling, J. Am. Coll. Cardiol. (2008) 755\u2013757."},{"key":"10.1016\/j.bcp.2020.114057_b0305","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","article-title":"Renin-angiotensin system revisited","volume":"264","author":"Fyhrquist","year":"2008","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bcp.2020.114057_b0310","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/Angiotensin-(1\u20137)\/MAS axis of the Renin-Angiotensin system: focus on Angiotensin-(1\u20137)","volume":"98","author":"Santos","year":"2017","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bcp.2020.114057_b0315","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0303-7207(92)90101-B","article-title":"Role of angiotensin II receptor subtypes on the regulation of aldosterone secretion in the adrenal glomerulosa zone in the rat","volume":"90","author":"Aguilera","year":"1992","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2020.114057_b0320","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/emmm.201000080","article-title":"Angiotensin II revisited: new roles in inflammation, immunology and aging","volume":"2","author":"Benigni","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcp.2020.114057_b0325","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coph.2017.12.002","article-title":"Targeting the renin\u2013angiotensin system as novel therapeutic strategy for pulmonary diseases","volume":"40","author":"Tan","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114057_b0330","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14728222.2013.827664","article-title":"Targeting the \u2018Janus face\u2019\u2019 of the B2-bradykinin receptor\u2019","volume":"17","author":"Blaes","year":"2013","journal-title":"Expert Opin. Ther. Targets."},{"key":"10.1016\/j.bcp.2020.114057_b0335","first-page":"1080","article-title":"Responses of serum and lung angiotensin-converting enzyme activities in the early phase of pulmonary damage induced by oleic acid in dogs","volume":"126","author":"Nukiwa","year":"1982","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.bcp.2020.114057_b0340","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.bcp.2020.114057_b0345","article-title":"Intrapulmonary activation of the angiotensin-converting enzyme type 2\/angiotensin 1\u20137\/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia","volume":"64","author":"Hampl","year":"2015","journal-title":"Physiol. Res."},{"key":"10.1016\/j.bcp.2020.114057_b0350","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.cellsig.2014.06.011","article-title":"A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology","volume":"26","author":"Balakumar","year":"2014","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bcp.2020.114057_b0355","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0014-5793(94)00531-1","article-title":"Activation of human peripheral monocytes by angiotensin II","volume":"347","author":"Hahn","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2020.114057_b0360","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1161\/01.RES.84.6.695","article-title":"Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors","volume":"84","author":"Han","year":"1999","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2020.114057_b0365","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0735-1097(99)00594-X","article-title":"Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure","volume":"35","author":"Tsutamoto","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2020.114057_b0370","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.00180","article-title":"The selective angiotensin II type 2 receptor agonist, compound 21, attenuates the progression of lung fibrosis and pulmonary hypertension in an experimental model of bleomycin-induced lung injury","volume":"9","author":"Rathinasabapathy","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bcp.2020.114057_b0375","doi-asserted-by":"crossref","DOI":"10.1007\/s11906-013-0416-6","article-title":"AT2 receptor and tissue injury: therapeutic implications topical collection on mediators, mechanisms, and pathways in tissue injury","volume":"16","author":"Namsolleck","year":"2014","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.bcp.2020.114057_b0380","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/157016106775203126","article-title":"Angiotensin II regulates vascular and endothelial dysfunction: recent topics of angiotensin II Type-1 receptor signaling in the vasculature","volume":"4","author":"Nakashima","year":"2005","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114057_b0385","doi-asserted-by":"crossref","first-page":"C1181","DOI":"10.1152\/ajpcell.00328.2010","article-title":"Angiotensin II-induced vascular endothelial dysfunction through RhoA\/Rho kinase\/p38 mitogen-activated protein kinase\/arginase pathway","volume":"300","author":"Shatanawi","year":"2011","journal-title":"Am. J. Physiol. - Cell Physiol."},{"key":"10.1016\/j.bcp.2020.114057_b0390","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/00004872-200406000-00005","article-title":"Angiotensin II, platelets and oxidative stress","volume":"22","author":"Duprez","year":"2004","journal-title":"J. Hypertens."},{"key":"10.1016\/j.bcp.2020.114057_b0395","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.HYP.30.1.29","article-title":"Role for endothelin-1 in angiotensin II-mediated hypertension","volume":"30","author":"Rajagopalan","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2020.114057_b0400","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00005-014-0310-1","article-title":"The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis","volume":"63","author":"Kowalczyk","year":"2015","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)"},{"key":"10.1016\/j.bcp.2020.114057_b0405","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/rr44","article-title":"Role of endothelin-1 in lung disease","volume":"2","author":"Fagan","year":"2001","journal-title":"Respir. Res."},{"key":"10.1016\/j.bcp.2020.114057_b0410","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.114057_b0415","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s003950050170","article-title":"Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-\u03baB in human vascular smooth muscle cells","volume":"95","author":"Browatzki","year":"2000","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.bcp.2020.114057_b0420","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1161\/01.HYP.22.6.853","article-title":"Effects of angiotensin II and endothelin-1 on platelet aggregation and cytosolic pH and free Ca2+ concentrations in essential hypertension","volume":"22","author":"Touyz","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2020.114057_b0425","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2337\/dc06-1793","article-title":"Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity","volume":"30","author":"Esteve","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2020.114057_b0430","unstructured":"Y. Pirahanchi, K.N. Brown, Physiology, Endothelial Derived Relaxation Factor (EDRF), 2019."},{"key":"10.1016\/j.bcp.2020.114057_b0435","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1748-1716.2009.01964.x","article-title":"Endothelial dysfunction and vascular disease","volume":"196","author":"Vanhoutte","year":"2009","journal-title":"Acta Physiol."},{"key":"10.1016\/j.bcp.2020.114057_b0440","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(87)91481-4","article-title":"Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium","volume":"330","author":"Radomski","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2020.114057_b0445","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1073\/pnas.88.11.4651","article-title":"Nitric oxide: An endogenous modulator of leukocyte adhesion","volume":"88","author":"Kubes","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2020.114057_b0450","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/HJH.0b013e32833992ef","article-title":"Interleukin-6 inhibits endothelial nitric oxide synthase activation and increases endothelial nitric oxide synthase binding to stabilized caveolin-1 in human vascular endothelial cells","volume":"28","author":"Hung","year":"2010","journal-title":"J. Hypertens."},{"key":"10.1016\/j.bcp.2020.114057_b0455","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.RES.0000115557.25127.8D","article-title":"Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II Type 1 receptor","volume":"94","author":"Wassmann","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2020.114057_b0460","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1161\/01.CIR.98.24.2652","article-title":"Endothelium as a therapeutic target in heart failure","volume":"98","author":"Drexler","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2020.114057_b0465","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1476-5381.2009.00240.x","article-title":"Endothelium-dependent contractions and endothelial dysfunction in human hypertension","volume":"157","author":"Versari","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114057_b0470","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bjp.0703393","article-title":"Endothelial dysfunction in diabetes","volume":"130","author":"De Vriese","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114057_b0475","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/blood-2008-04-144758","article-title":"Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment","volume":"112","author":"Stoll","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2020.114057_b0480","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5114\/ceji.2019.87498","article-title":"Analysis of the level of selected parameters of inflammation, circulating immune complexes, and related indicators (neutrophil\/ lymphocyte, platelet\/lymphocyte, CRP\/CIC) in patients with obstructive diseases","volume":"44","author":"Pilaczy\u0144ska-Cemel","year":"2019","journal-title":"Cent. Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2020.114057_b0485","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00424-009-0763-y","article-title":"Endothelium-derived endothelin-1","volume":"459","author":"Thorin","year":"2010","journal-title":"Pflugers Arch. Eur. J. Physiol."},{"key":"10.1016\/j.bcp.2020.114057_b0490","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","article-title":"Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis","volume":"98","author":"Kaser","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2020.114057_b0495","first-page":"545","article-title":"Endothelin stimulates platelet-activating factor synthesis by cultured rat Kupffer cells","volume":"21","author":"Mustafa","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2020.114057_b0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161988","article-title":"Stimulation of transforming growth factor-\u03b21-induced endothelial-to-mesenchymal transition and tissue fibrosis by endothelin-1 (ET-1): a novel profibrotic effect of ET-1","volume":"11","author":"Wermuth","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2020.114057_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30225-3","article-title":"Personal view pulmonary fibrosis and COVID- 19: the potential role for antifibrotic therapy","author":"George","year":"2020","journal-title":"Lancet Respir."},{"key":"10.1016\/j.bcp.2020.114057_b0510","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1161\/01.HYP.0000185148.27901.fe","article-title":"Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutrition-programmed hypertension in the adult rat","volume":"46","author":"Rivi\u00e8re","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2020.114057_b0515","doi-asserted-by":"crossref","unstructured":"C. Bavishi, T.M. Maddox, F.H. Messerli, Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers, JAMA Cardiol. (2020).","DOI":"10.1001\/jamacardio.2020.1282"},{"key":"10.1016\/j.bcp.2020.114057_b0520","doi-asserted-by":"crossref","first-page":"14838","DOI":"10.1074\/jbc.M200581200","article-title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase","volume":"277","author":"Vickers","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114057_b0525","doi-asserted-by":"crossref","unstructured":"A.C. Sim\u00f5es E Silva, K.D. Silveira, A.J. Ferreira, M.M. Teixeira, ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis, Br. J. Pharmacol. 169 (2013) 477\u2013492.","DOI":"10.1111\/bph.12159"},{"key":"10.1016\/j.bcp.2020.114057_b0530","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/ar3052","article-title":"Angiotensin-converting enzyme 2 autoantibodies: further evidence for a role of the renin-angiotensin system in inflammation","volume":"12","author":"Chappell","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bcp.2020.114057_b0535","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.1038\/srep08209","article-title":"Angiotensin-converting enzyme 2\/angiotensin-(1\u20137)\/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK\/NF-\u03baB pathways","volume":"5","author":"Li","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2020.114057_b0540","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.bcp.2020.114057_b0545","first-page":"E014","article-title":"Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia","volume":"43","author":"Sun","year":"2020","journal-title":"Chinese J. Tuberc. Respir. Dis."},{"key":"10.1016\/j.bcp.2020.114057_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2020.114057_b0555","doi-asserted-by":"crossref","unstructured":"K. Dhama, K. Sharun, R. Tiwari, M. Dadar, Y.S. Malik, K.P. Singh, W. Chaicumpa, COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics, Hum. Vaccin. Immunother. (2020) 1\u20137.","DOI":"10.1080\/21645515.2020.1735227"},{"key":"10.1016\/j.bcp.2020.114057_b0560","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2020.114057_b0565","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Correspondence Endothelial cell infection and endotheliitis in","volume":"395","author":"Varga","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2020.114057_b0570","doi-asserted-by":"crossref","unstructured":"Y. Zhao, Z. Zhao, Y. Wang, Y. Zhou, Y. Ma, W. Zuo, Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov, BioRxiv. (2020).","DOI":"10.1101\/2020.01.26.919985"},{"key":"10.1016\/j.bcp.2020.114057_b0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035876","article-title":"Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts","volume":"7","author":"Bertram","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2020.114057_b0580","article-title":"SARS-CoV-2 receptor ACE2 and TMPRSS2 are predominantly expressed in a transient secretory cell type in subsegmental bronchial branches","author":"Lukassen","year":"2020","journal-title":"BioRxiv."},{"key":"10.1016\/j.bcp.2020.114057_b0585","doi-asserted-by":"crossref","unstructured":"G. Li, R. Hu, X. Zhang, Antihypertensive treatment with ACEI\/ARB of patients with COVID-19 complicated by hypertension, Hypertens. Res. (2020) 1\u20133.","DOI":"10.1038\/s41440-020-0433-1"},{"key":"10.1016\/j.bcp.2020.114057_b0590","doi-asserted-by":"crossref","unstructured":"L. Guo, D. Li, H. Yang, L. Liu, J. Fan, Potential pathogenesis of multiple organ injury in COVID-19, Preprint. (2020).","DOI":"10.20944\/preprints202003.0308.v1"},{"key":"10.1016\/j.bcp.2020.114057_b0595","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/jgh.15047","article-title":"Covid-19 and the digestive system","volume":"35","author":"Wong","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2020.114057_b0600","article-title":"COVID-19\u2013associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features","volume":"201187","author":"Poyiadji","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.bcp.2020.114057_b0605","doi-asserted-by":"crossref","DOI":"10.5812\/ircmj.102828","article-title":"Frequent convulsive seizures in an adult patient with COVID-19: a case report","volume":"22","author":"Karimi","year":"2020","journal-title":"Iran. Red Crescent Med. J."},{"key":"10.1016\/j.bcp.2020.114057_b0610","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4812","article-title":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?","author":"Patel","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2020.114057_b0615","unstructured":"M.L. Chiusano, The modelling of COVID19 pathways sheds light on mechanisms, opportunities and on controversial interpretations of medical treatments. v2, ArXiv Prepr. ArXiv2003.11614. (2020)."},{"key":"10.1016\/j.bcp.2020.114057_b0620","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/path.2987","article-title":"Acute respiratory distress syndrome leads to reduced ratio of ACE\/ACE2 activities and is prevented by angiotensin-(1\u20137) or an angiotensin II receptor antagonist","volume":"225","author":"W\u00f6sten-Van Asperen","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.bcp.2020.114057_b0625","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1164\/rccm.200912-1840OC","article-title":"The angiotensin-converting enzyme 2\/angiogenesis-(1\u20137)\/mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension","volume":"182","author":"Shenoy","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bcp.2020.114057_b0630","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijcard.2014.08.021","article-title":"Decreased levels of serum Angiotensin-(1\u20137) in patients with pulmonary arterial hypertension due to congenital heart disease","volume":"176","author":"Dai","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.bcp.2020.114057_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101833","article-title":"Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation","volume":"58","author":"Wang","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.114057_b0640","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1086\/683696","article-title":"Dose-dependent, therapeutic potential of angiotensin-(1\u20137) for the treatment of pulmonary arterial hypertension","volume":"5","author":"Breitling","year":"2015","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.bcp.2020.114057_b0645","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1042\/CS20160243","article-title":"Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease","volume":"130","author":"Chow","year":"2016","journal-title":"Clin. Sci."},{"key":"10.1016\/j.bcp.2020.114057_b0650","article-title":"Angiotensin-(1\u20137): a novel peptide to treat hypertension and nephropathy in diabetes?","volume":"6","author":"Padda","year":"2015","journal-title":"J. Diabetes Metab."},{"key":"10.1016\/j.bcp.2020.114057_b0655","doi-asserted-by":"crossref","first-page":"H1171","DOI":"10.1152\/ajpheart.00897.2014","article-title":"Differences in angiotensin (1\u20137) between men and women","volume":"308","author":"Sullivan","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bcp.2020.114057_b0660","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2119\/2007-00073.Fraga-Silva","article-title":"The antithrombotic effect of angiotensin-(1\u20137) involves mas-mediated NO release from platelets","volume":"14","author":"Fraga-Silva","year":"2008","journal-title":"Mol. Med."},{"key":"10.1016\/j.bcp.2020.114057_b0665","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1089\/ars.2012.4614","article-title":"Angiotensin peptides and nitric oxide in cardiovascular disease","volume":"19","author":"Patel","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bcp.2020.114057_b0670","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/ajh\/hpy006","article-title":"Modulating role of Ang1-7 in control of blood pressure and renal function in AngII-infused hypertensive rats","volume":"31","author":"Kuczeriszka","year":"2017","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.bcp.2020.114057_b0675","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejphar.2010.04.030","article-title":"Angiotensin-(1\u20137) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities","volume":"638","author":"Dhaunsi","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114057_b0680","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fimmu.2018.00058","article-title":"Angiotensin-(1\u20137) promotes resolution of eosinophilic inflammation in an experimental model of asthma","volume":"9","author":"Magalhaes","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2020.114057_b0685","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1165\/rcmb.2012-0451OC","article-title":"Angiotensin-converting enzyme 2\/angiotensin-(1\u20137)\/mas axis protects against lung fibrosis by inhibiting the MAPK\/NF-\u03baB pathway","volume":"50","author":"Meng","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.bcp.2020.114057_b0690","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1089\/ars.2014.6070","article-title":"Upregulation of angiotensin (1\u20137)-mediated signaling preserves endothelial function through reducing oxidative stress in diabetes","volume":"23","author":"Zhang","year":"2015","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.bcp.2020.114057_b0695","doi-asserted-by":"crossref","unstructured":"M. Shao, Z. Bin Wen, H.H. Yang, C.Y. Zhang, J.B. Xiong, X.X. Guan, W.J. Zhong, H.L. Jiang, C.C. Sun, X.Q. Luo, X. an He, Y. Zhou, C.X. Guan, Exogenous angiotensin (1-7) directly inhibits epithelial-mesenchymal transformation induced by transforming growth factor-\u03b21 in alveolar epithelial cells, Biomed. Pharmacother. 117 (2019) 109193.","DOI":"10.1016\/j.biopha.2019.109193"},{"key":"10.1016\/j.bcp.2020.114057_b0700","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3892\/ijmm.2016.2823","article-title":"Bach1 siRNA attenuates bleomycin-induced pulmonary fibrosis by modulating oxidative stress in mice","volume":"39","author":"Liu","year":"2017","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bcp.2020.114057_b0705","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3389\/fphar.2016.00482","article-title":"The Angiotensin-(1\u20137)\/mas axis counteracts Angiotensin II-dependent and -independent pro-inflammatory signaling in human vascular smooth muscle cells","volume":"7","author":"Villalobos","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114057_b0710","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/qjmed\/hcz206","article-title":"Angiotensin-converting enzyme 2 attenuates inflammatory response and oxidative stress in hyperoxic lung injury by regulating NF-kappaB and Nrf2 pathways","volume":"112","author":"Fang","year":"2019","journal-title":"QJM"},{"key":"10.1016\/j.bcp.2020.114057_b0715","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/jcm9010267","article-title":"The vasoactive mas receptor in essential hypertension","volume":"9","author":"Povlsen","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2020.114057_b0720","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1111\/bph.13057","article-title":"Angiotensin-(1\u20137) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation","volume":"172","author":"Magalhaes","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114057_b0725","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","article-title":"Angiotensin-converting enzyme 2 and angiotensin 1\u20137: novel therapeutic targets","volume":"11","author":"Jiang","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.bcp.2020.114057_b0730","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.HYP.0000037979.53963.8F","article-title":"AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1\u20137) on the endothelium","volume":"40","author":"Wiemer","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2020.114057_b0735","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.peptides.2007.08.011","article-title":"Study of angiotensin-(1\u20137) vasoactive peptide and its \u03b2-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies","volume":"28","author":"Lula","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.bcp.2020.114057_b0740","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1161\/HYPERTENSIONAHA.110.152942","article-title":"Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor","volume":"56","author":"Savergnini","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2020.114057_b0745","first-page":"482","article-title":"NorLeu3-A(1\u20137) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial","volume":"20","author":"Balingit","year":"2012","journal-title":"Wound Repair Regen. Off. Publ. Wound Heal. Soc. Eur. Tissue Repair Soc."},{"key":"10.1016\/j.bcp.2020.114057_b0750","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.kint.2019.04.024","article-title":"Addition of cyclic angiotensin-(1\u20137) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy","volume":"96","author":"Cassis","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcp.2020.114057_b0755","article-title":"Angiotensin-(1\u20137)\/Angiotensin-converting enzyme 2\/mas receptor axis and related mechanisms","volume":"2012","author":"Ferreira","year":"2012","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.bcp.2020.114057_b0760","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1097\/HJH.0b013e3282f0143c","article-title":"Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function","volume":"25","author":"Peir\u00f3","year":"2007","journal-title":"J. Hypertens."},{"key":"10.1016\/j.bcp.2020.114057_b0765","article-title":"Role of mas receptor Antagonist A799 in renal blood flow response to Ang 1\u20137 after bradykinin administration in ovariectomized estradiol-treated rats","volume":"2015","author":"Dehghani","year":"2015","journal-title":"Adv. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2020.114057_b0770","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.peptides.2006.10.007","article-title":"Evidence for a new angiotensin-(1\u20137) receptor subtype in the aorta of Sprague-Dawley rats","volume":"28","author":"Silva","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.bcp.2020.114057_b0775","doi-asserted-by":"crossref","unstructured":"T. Beril, de V. Ren\u00e9, S.P. R., D.A.H. Jan, Bradykinin Potentiation by Angiotensin-(1-7) and ACE Inhibitors Correlates With ACE C- and N-Domain Blockade, Hypertension. 38 (2001) 95\u201399.","DOI":"10.1161\/01.HYP.38.1.95"},{"key":"10.1016\/j.bcp.2020.114057_b0780","first-page":"124","article-title":"The kinin system\u2013bradykinin: biological effects and clinical implications. Multiple role of the kinin system\u2013bradykinin","volume":"11","author":"Golias","year":"2007","journal-title":"Hippokratia."},{"key":"10.1016\/j.bcp.2020.114057_b0785","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1165\/rcmb.2002-0040OC","article-title":"Bradykinin induces interleukin-6 production in human airway smooth muscle cells: modulation by Th2 cytokines and dexamethasone","volume":"28","author":"Da Huang","year":"2003","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.bcp.2020.114057_b0790","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF02032574","article-title":"Release of cytokines from isolated lung strips by bradykinin","volume":"44","author":"Paegelow","year":"1995","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.bcp.2020.114057_b0795","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1172\/JCI119009","article-title":"Bradykinin stimulates NF-\u03baB activation and interleukin 1\u03b2 gene expression in cultured human fibroblasts","volume":"98","author":"Pan","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2020.114057_b0800","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1165\/ajrcmb.22.1.3752","article-title":"Bradykinin stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activity","volume":"22","author":"Koyama","year":"2000","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.bcp.2020.114057_b0805","doi-asserted-by":"crossref","unstructured":"L. de S. Silva, D. de B. Peruchetti, C.T.F.-D. Silva, A.T. Ferreira-DaSilva, J. Perales, C. Caruso-Neves, A.A.S. Pinheiro, Interaction between bradykinin B2 and Ang-(1\u20137) Mas receptors regulates erythrocyte invasion by Plasmodium falciparum, Biochim. Biophys. Acta - Gen. Subj. 1860 (2016) 2438\u20132444.","DOI":"10.1016\/j.bbagen.2016.07.011"},{"key":"10.1016\/j.bcp.2020.114057_b0810","doi-asserted-by":"crossref","unstructured":"K. Yamamoto, M.C. Chappell, K.B. Brosnihan, C.M. Ferrario, In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4. 24.11) in spontaneously hypertensive rats, Hypertension. 19 (1992) 692\u2013696.","DOI":"10.1161\/01.HYP.19.6.692"},{"key":"10.1016\/j.bcp.2020.114057_b0815","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1210\/en.2014-1685","article-title":"Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats","volume":"156","author":"Roman\u00ed-P\u00e9rez","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2020.114057_b0820","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1183\/09031936.95.08091458","article-title":"Localization of neutral endopeptidase (NEP) mRNA in human bronchi","volume":"8","author":"Baraniuk","year":"1995","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bcp.2020.114057_b0825","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/S0024-3205(02)01990-2","article-title":"Increased expression of renal neutral endopeptidase in severe heart failure","volume":"71","author":"Knecht","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2020.114057_b0830","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/stem.592","article-title":"Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer","volume":"29","author":"Maguer-Satta","year":"2011","journal-title":"Stem Cells."},{"key":"10.1016\/j.bcp.2020.114057_b0835","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000087476","article-title":"Anti-progressive effect of neutral endopeptidase 24.11 (NEP\/CD10) on cervical carcinoma in vitro and in vivo","volume":"69","author":"Terauchi","year":"2005","journal-title":"Oncology."},{"key":"10.1016\/j.bcp.2020.114057_b0840","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10549-007-9516-9","article-title":"On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer","volume":"106","author":"Smollich","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2020.114057_b0845","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/gut.2009.178376","article-title":"CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver","volume":"59","author":"Kuniyasu","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2020.114057_b0850","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/s41598-019-38867-2","article-title":"The circulating form of neprilysin is not a general biomarker for overall survival in treatment-na\u00efve cancer patients","volume":"9","author":"Pavo","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2020.114057_b0855","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jmb.2009.08.025","article-title":"Structural substrate conditions required for neutral endopeptidase-mediated natriuretic peptide degradation","volume":"393","author":"Pankow","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bcp.2020.114057_b0860","doi-asserted-by":"crossref","unstructured":"R.A. Ervin, G. Skidgel, Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones1, FASEB J. 3 (1989) 145\u2013151.","DOI":"10.1096\/fasebj.3.2.2521610"},{"key":"10.1016\/j.bcp.2020.114057_b0865","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics","volume":"34","author":"Mangiafico","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2020.114057_b0870","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/CS20150469","article-title":"The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment","volume":"130","author":"Volpe","year":"2016","journal-title":"Clin. Sci. (Lond)"},{"key":"10.1016\/j.bcp.2020.114057_b0875","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1161\/01.HYP.20.1.89","article-title":"Role of neutral endopeptidase in the metabolism of endothelin","volume":"20","author":"Abassi","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2020.114057_b0880","doi-asserted-by":"crossref","DOI":"10.1016\/S0031-6997(25)00449-1","article-title":"Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology","author":"Roques","year":"1993","journal-title":"Pharmacol. Rev. 45"},{"key":"10.1016\/j.bcp.2020.114057_b0885","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1369\/0022155418765164","article-title":"neprilysin deficiency is associated with expansion of Islet \u03b2-cell mass in high fat-fed mice","volume":"66","author":"Parilla","year":"2018","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.bcp.2020.114057_b0890","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0008-6363(01)00289-9","article-title":"Atrial natriuretic peptide mimetics and vasopeptidase inhibitors","volume":"51","author":"Sagnella","year":"2001","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2020.114057_b0895","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cardiores.2005.10.001","article-title":"The role of natriuretic peptides in cardioprotection","volume":"69","author":"Nishikimi","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2020.114057_b0900","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2020.114057_b0905","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1124\/jpet.115.231167","article-title":"Pharmacologic comparison of clinical neutral endopeptidase inhibitors in a rat model of acute secretory diarrheas","volume":"357","author":"Griggs","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.114057_b0910","doi-asserted-by":"crossref","unstructured":"Y. Khder, V. Shi, J.J.V. McMurray, M.P. Lefkowitz, Sacubitril\/valsartan (LCZ696) in heart failure, in: Handb. Exp. Pharmacol., Springer New York LLC, 2017, pp. 133\u2013165.","DOI":"10.1007\/164_2016_77"},{"key":"10.1016\/j.bcp.2020.114057_b0915","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1527-3466.2000.tb00051.x","article-title":"The therapeutic potential of candoxatril, a neutral endopeptidase inhibitor, in humans","volume":"18","author":"McDowell","year":"2000","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.bcp.2020.114057_b0920","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11897-015-0270-8","article-title":"The role of neprilysin inhibitors in cardiovascular disease","volume":"12","author":"Mills","year":"2015","journal-title":"Curr. Heart Fail. Rep."},{"key":"10.1016\/j.bcp.2020.114057_b0925","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2337\/db18-1825-P","article-title":"Pharmacological neprilysin inhibition improves glucose homeostasis in a mouse model of type 2 diabetes","volume":"67","author":"Parilla","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2020.114057_b0930","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fnagi.2014.00187","article-title":"Amyloid-beta and Alzheimer\u2019s disease: the role of neprilysin-2 in amyloid-beta clearance","volume":"6","author":"Marr","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.bcp.2020.114057_b0935","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0196-9781(95)00021-B","article-title":"Neutral endopeptidase can hydrolyze \u03b2-amyloid (1\u201340) but shows no effect on \u03b2-amyloid precursor protein metabolism","volume":"16","author":"Howell","year":"1995","journal-title":"Peptides"},{"key":"10.1016\/j.bcp.2020.114057_b0940","doi-asserted-by":"crossref","unstructured":"N. Iwata, S. Tsubuki, Y. Takaki, K. Shirotani, B. Lu, N.P. Gerard, C. Gerard, E. Hama, H.J. Lee, T.C. Saido, Metabolic regulation of brain A\u03b2 by neprilysin, Science (80-.). 292 (2001) 1550\u20131552.","DOI":"10.1126\/science.1059946"},{"key":"10.1016\/j.bcp.2020.114057_b0945","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.febslet.2013.12.038","article-title":"The dark sides of amyloid in Alzheimer\u2019s disease pathogenesis","volume":"588","author":"Sorrentino","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2020.114057_b0950","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.bbrc.2016.06.103","article-title":"Protective effect of recombinant soluble neprilysin against \u03b2-amyloid induced neurotoxicity","volume":"477","author":"Oh","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2020.114057_b0955","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/15376510902725649","article-title":"Mechanisms of toxic smoke inhalation and burn injury: role of neutral endopeptidase and vascular leakage in mice","volume":"19","author":"Jacob","year":"2009","journal-title":"Toxicol. Mech. Methods."},{"key":"10.1016\/j.bcp.2020.114057_b0960","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/rccm.200907-1073OC","article-title":"Early protection from burn-induced acute lung injury by deletion of preprotachykinin-A gene","volume":"181","author":"Sio","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bcp.2020.114057_b0965","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.rmed.2005.10.024","article-title":"Neuroendocrine cell hyperplasia as an unusual form of interstitial lung disease","volume":"101","author":"Reyes","year":"2007","journal-title":"Respir. Med."},{"key":"10.1016\/j.bcp.2020.114057_b0970","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1183\/09031936.00109409","article-title":"Diffuse idiopathic pulmonary neuroendocrine hyperplasia, chronic eosinophilic pneumonia, and asthma","volume":"34","author":"Sanaee","year":"2009","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bcp.2020.114057_b0975","first-page":"72","article-title":"Oxygen, gastrin-releasing Peptide, and pediatric lung disease: life in the balance","volume":"2","author":"Sunday","year":"2014","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.bcp.2020.114057_b0980","doi-asserted-by":"crossref","DOI":"10.1172\/JCI114782","article-title":"Increased pulmonary neuroendocrine cells with bombesin-like immunoreactivity in adult patients with eosinophilic granuloma","volume":"86","author":"Aguayo","year":"1990","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2020.114057_b0985","first-page":"171","article-title":"Pulmonary neuroendocrine cells (PNEC) and neuroepithelial bodies (NEB): chemoreceptors and regulators of lung development","volume":"2","author":"Van Lommel","year":"2001","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.bcp.2020.114057_b0990","doi-asserted-by":"crossref","first-page":"17531","DOI":"10.1073\/pnas.1207238109","article-title":"Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis","volume":"109","author":"Song","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2020.114057_b0995","doi-asserted-by":"crossref","unstructured":"K. Branchfield, L. Nantie, J.M. Verheyden, P. Sui, M.D. Wienhold, X. Sun, Pulmonary neuroendocrine cells function as airway sensors to control lung immune response, Science (80-.). 351 (2016) 707\u2013710.","DOI":"10.1126\/science.aad7969"},{"key":"10.1016\/j.bcp.2020.114057_b1000","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1164\/rccm.2510002","article-title":"Bombesin-like peptides: modulators of inflammation in acute lung injury?","volume":"173","author":"Ganter","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bcp.2020.114057_b1005","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1073\/pnas.1110996109","article-title":"Gastrin-releasing peptide receptor (GRPR) mediates chemotaxis in neutrophils","volume":"109","author":"Czepielewski","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2020.114057_b1010","doi-asserted-by":"crossref","unstructured":"W. MacNee, Pulmonary neutrophil kinetics., Clin. Phys. Physiol. Meas. 11 Suppl A (1990) 133\u2013139.","DOI":"10.1088\/0143-0815\/11\/4A\/319"},{"key":"10.1016\/j.bcp.2020.114057_b1015","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/thoraxjnl-2013-204742","article-title":"Pulmonary retention of primed neutrophils: a novel protective host response, which is impaired in the acute respiratory distress syndrome","volume":"69","author":"Summers","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.bcp.2020.114057_b1020","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.ijid.2012.06.006","article-title":"Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia","volume":"17","author":"Bordon","year":"2013","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.bcp.2020.114057_b1025","doi-asserted-by":"crossref","unstructured":"M.A. Shipp, G.E. Tarr, C.Y. Chen, S.N. Switzer, L.B. Hersh, H. Stein, M.E. Sunday, E.L. Reinherz, CD10\/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung, Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 10662\u201310666.","DOI":"10.1073\/pnas.88.23.10662"},{"key":"10.1016\/j.bcp.2020.114057_b1030","doi-asserted-by":"crossref","unstructured":"J.C. Connelly, R.A. Skidgel, W.W. Schulz, A.R. Johnson, E.G. Erd\u00f6s, Neutral endopeptidase 24.11 in human neutrophils: Cleavage of chemotactic peptide, Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 8737\u20138741.","DOI":"10.1073\/pnas.82.24.8737"},{"key":"10.1016\/j.bcp.2020.114057_b1035","doi-asserted-by":"crossref","unstructured":"R.G. Painter, R. Dukes, J. Sullivan, R. Carter, E.G. Erdos, A.R. Johnson, Function of Neutral Endopeptidase on the Cell Membrane of Human Neutrophils, J. Biol. Chem. 263 (1988) 9456\u20139461.","DOI":"10.1016\/S0021-9258(19)76562-4"},{"key":"10.1016\/j.bcp.2020.114057_b1040","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1172\/JCI113970","article-title":"Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages","volume":"83","author":"Savill","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2020.114057_b1045","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nri1841","article-title":"Neutrophil serine proteases: specific regulators of inflammation","volume":"6","author":"Pham","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2020.114057_b1050","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.2741\/3462","article-title":"Neutrophil-derived serine proteases modulate innate immune responses","author":"Meyer-Hoffert","year":"2009","journal-title":"Front. Biosci."},{"key":"10.1016\/j.bcp.2020.114057_b1055","doi-asserted-by":"crossref","first-page":"8619","DOI":"10.1016\/S0021-9258(18)34171-1","article-title":"Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases","volume":"257","author":"Reilly","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114057_b1060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1006\/abbi.2001.2687","article-title":"Release and degradation of angiotensin I and angiotensin II from angiotensinogen by neutrophil serine proteinases","volume":"397","author":"Ramaha","year":"2002","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2020.114057_b1065","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.4049\/jimmunol.160.3.1436","article-title":"Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition","volume":"160","author":"Owen","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2020.114057_b1070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2020.114057_b1075","doi-asserted-by":"crossref","first-page":"F841","DOI":"10.1152\/ajprenal.2000.279.5.F841","article-title":"Pathways for angiotensin-(1\u20137) metabolism in pulmonary and renal tissues","volume":"279","author":"Allred","year":"2000","journal-title":"Am. J. Physiol. Physiol."},{"key":"10.1016\/j.bcp.2020.114057_b1080","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","article-title":"Long-term neprilysin inhibition \u2014 implications for ARNIs","volume":"14","author":"Campbell","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.bcp.2020.114057_b1085","doi-asserted-by":"crossref","unstructured":"Y. Song, M. Zhang, L. Yin, K. Wang, Y. Zhou, M. Zhou, Y. Lu, COVID-19 treatment: close to a cure\u00a0? A rapid review of pharmacotherapies for the novel coronavirus, Med. Pharmacol. (2020) 1\u201325.","DOI":"10.20944\/preprints202003.0378.v1"},{"key":"10.1016\/j.bcp.2020.114057_b1090","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/jcm8060786","article-title":"Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients","volume":"8","author":"Voiriot","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2020.114057_b1095","article-title":"Non-steroidal anti-inflammatory drugs and covid-19","volume":"368","author":"Little","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.bcp.2020.114057_b1100","doi-asserted-by":"crossref","unstructured":"R. Gupta, A. Misra, Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in co-morbid diseases (Hypertension, Diabetes etc), Diabetes Metab. Syndr. Clin. Res. Rev. (2020).","DOI":"10.1016\/j.dsx.2020.03.012"},{"key":"10.1016\/j.bcp.2020.114057_b1105","doi-asserted-by":"crossref","first-page":"m1086","DOI":"10.1136\/bmj.m1086","article-title":"Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists","volume":"368","author":"Day","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.bcp.2020.114057_b1110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1165\/ajrcmb.16.5.9160837","article-title":"Enhanced expression of neutral endopeptidase (NEP) in airway epithelium in biopsies from steroid- versus nonsteroid-treated patients with atopic asthma","volume":"16","author":"Sont","year":"1997","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.bcp.2020.114057_b1115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2020.114057_b1120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jinf.2004.09.008","article-title":"The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study","volume":"51","author":"Auyeung","year":"2005","journal-title":"J. Infect."},{"key":"10.1016\/j.bcp.2020.114057_b1125","doi-asserted-by":"crossref","unstructured":"Y.M. Arabi, Y. Mandourah, F. Al-Hameed, A.A. Sindi, G.A. Almekhlafi, M.A. Hussein, J. Jose, R. Pinto, A. Al-Omari, A. Kharaba, A. Almotairi, K. Al Khatib, B. Alraddadi, S. Shalhoub, A. Abdulmomen, I. Qushmaq, A. Mady, O. Solaiman, A.M. Al-Aithan, R. Al-Raddadi, A. Ragab, H.H. Balkhy, A. Al Harthy, A.M. Deeb, H. Al Mutairi, A. Al-Dawood, L. Merson, F.G. Hayden, R.A. Fowler, Corticosteroid therapy for critically ill patients with middle east respiratory syndrome., Am. J. Respir. Crit. Care Med. 197 (2018) 757\u2013767.","DOI":"10.1164\/rccm.201706-1172OC"},{"key":"10.1016\/j.bcp.2020.114057_b1130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.bcp.2020.114057_b1135","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19","volume":"177","author":"Touret","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2020.114057_b1140","doi-asserted-by":"crossref","unstructured":"P. Gautret, J.-C. Lagier, P. Parola, V.T. Hoang, L. Meddeb, M. Mailhe, B. Doudier, J. Courjon, V. Giordanengo, V.E. Vieira, H.T. Dupont, S. Honor\u00e9, P. Colson, E. Chabri\u00e8re, B. La Scola, J.-M. Rolain, P. Brouqui, D. Raoult, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents. (2020).","DOI":"10.1101\/2020.03.16.20037135"},{"key":"10.1016\/j.bcp.2020.114057_b1145","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","author":"Cortegiani","year":"2020","journal-title":"J. Crit. Care."},{"key":"10.1016\/j.bcp.2020.114057_b1150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2006.06.012","article-title":"Statins and the endothelium","volume":"46","author":"Ii","year":"2007","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114057_b1155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/imm.12902","article-title":"Immune modulatory effects of statins","volume":"154","author":"Zeiser","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.bcp.2020.114057_b1160","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/phar.2397","article-title":"Considerations for statin therapy in patients with COVID-19","volume":"40","author":"Dashti-Khavidaki","year":"2020","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.bcp.2020.114057_b1165","doi-asserted-by":"crossref","unstructured":"M.R. Goldstein, G.A. Poland, C.W. Graeber, Are certain drugs associated with enhanced mortality in COVID-19?, QJM Int. J. Med. (2020).","DOI":"10.1093\/qjmed\/hcaa103"},{"key":"10.1016\/j.bcp.2020.114057_b1170","doi-asserted-by":"crossref","unstructured":"J. Li, Y. Zhang, F. Wang, B. Liu, H. Li, G. Tang, Z. Chang, A. Liu, C. Fu, J. Gao, J. Li, Sex differences in clinical findings among patients with coronavirus disease 2019 (COVID-19) and severe condition, MedRxiv. (2020) 2020.02.27.20027524.","DOI":"10.1101\/2020.02.27.20027524"},{"key":"10.1016\/j.bcp.2020.114057_b1175","doi-asserted-by":"crossref","unstructured":"X. Wang, R. Dhindsa, G. Povysil, A. Zoghbi, J. Motelow, J. Hostyk, D. Goldstein, Transcriptional Inhibition of Host Viral Entry Proteins as a Therapeutic Strategy for SARS-CoV-2, Preprints. (2020).","DOI":"10.20944\/preprints202003.0360.v1"},{"key":"10.1016\/j.bcp.2020.114057_b1180","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2020.114057_b1185","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.bcp.2020.114057_b1190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2015.11.004","article-title":"Estradiol, acting through ER\u03b1, induces endothelial non-classic renin-angiotensin system increasing angiotensin 1\u20137 production","volume":"422","author":"Mompe\u00f3n","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2020.114057_b1195","doi-asserted-by":"crossref","unstructured":"A.H.J. Danser, M. Epstein, D. Batlle, Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers, Hypertension. (2020) HYPERTENSIONAHA-120.","DOI":"10.1161\/HYPERTENSIONAHA.120.15082"},{"key":"10.1016\/j.bcp.2020.114057_b1200","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1165\/rcmb.2006-0429OC","article-title":"Stretch-induced alveolar type II cell apoptosis: role of endogenous bradykinin and PI3K-Akt signaling","volume":"37","author":"Hammerschmidt","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.bcp.2020.114057_b1205","unstructured":"D.A.H. Jan, E. Murray, B. Daniel, Renin-angiotensin system blockers and the COVID-19 pandemic, Hypertension. (2020) HYPERTENSIONAHA-120."},{"key":"10.1016\/j.bcp.2020.114057_b1210","doi-asserted-by":"crossref","unstructured":"S. Tian, W. Hu, L. Niu, H. Liu, H. Xu, S.Y. Xiao, Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer, J. Thorac. Oncol. (2020).","DOI":"10.20944\/preprints202002.0220.v2"},{"key":"10.1016\/j.bcp.2020.114057_b1215","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134529","article-title":"Gastrin releasing peptide-induced satiety is associated with hypothalamic and brainstem changes in chicks","volume":"713","author":"Bohler","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2020.114057_b1220","doi-asserted-by":"crossref","unstructured":"J. Liu, Y. Liu, P. Xiang, L. Pu, H. Xiong, C. Li, M. Zhang, J. Tan, Y. Xu, R. Song, M. Song, L. Wang, W. Zhang, B. Han, L. Yang, X. Wang, G. Zhou, T. Zhang, B. Li, Y. Wang, Z. Chen, X. Wang, Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage, MedRxiv. 807 (2020) 2020.02.10.20021584. doi:10.1101\/2020.02.10.20021584.","DOI":"10.1101\/2020.02.10.20021584"},{"key":"10.1016\/j.bcp.2020.114057_b1225","article-title":"Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study","volume":"20","author":"Pan","year":"2020","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.bcp.2020.114057_b1230","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcf.2004.06.006","article-title":"Cytokines and inflammatory mediators in cystic fibrosis","volume":"3","author":"Courtney","year":"2004","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.bcp.2020.114057_b1235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JIR.S4385","article-title":"Inflammatory mechanisms in the lung","volume":"2","author":"Yu","year":"2008","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.bcp.2020.114057_b1240","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1161\/01.HYP.31.6.1305","article-title":"Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase role of blood pressure and endothelial function","volume":"31","author":"D\u2019Uscio","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2020.114057_b1245","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00608.2009","article-title":"Angiotensin-(1\u20137) stimulates high atrial pacing-induced ANP secretion via Mas\/PI3-kinase\/Akt axis and Na+\/H+ exchanger","author":"Shah","year":"2010","journal-title":"Am. J. Physiol. - Hear. Circ. Physiol. 298"},{"key":"10.1016\/j.bcp.2020.114057_b1250","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.mce.2008.09.020","article-title":"The sweeter side of ACE2: Physiological evidence for a role in diabetes","volume":"302","author":"Bindom","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2020.114057_b1255","doi-asserted-by":"crossref","unstructured":"Z. Lang, C.G. Murlas, Dexamethasone Increases Airway Epithelial Cell Neutral Endopeptidase by Enhancing Transcription and New Protein Synthesis, 1993.","DOI":"10.1007\/BF00183945"},{"key":"10.1016\/j.bcp.2020.114057_b1260","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/cns.12186","article-title":"Valproic acid reduces neuritic plaque formation and improves learning deficits in APPSwe\/PS1A246E transgenic mice via preventing the prenatal hypoxia-induced down-regulation of neprilysin","volume":"20","author":"Wang","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bcp.2020.114057_b1265","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s40478-018-0640-z","article-title":"5-HIAA induces neprilysin to ameliorate pathophysiology and symptoms in a mouse model for Alzheimer\u2019s disease","volume":"6","author":"Klein","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.bcp.2020.114057_b1270","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/j.1471-4159.2008.05341.x","article-title":"Androgens regulate neprilysin expression: Role in reducing \u03b2-amyloid levels","volume":"105","author":"Yao","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2020.114057_b1275","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12031-008-9168-1","article-title":"Estrogen regulation of the neprilysin gene through a hormone-responsive element","volume":"39","author":"Xiao","year":"2009","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.bcp.2020.114057_b1280","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/13880200802055891","article-title":"Influence of selected natural products on neutral endopeptidase activity and \u03b2-Amyloid production in SK-N-SH cells","volume":"46","author":"Ayoub","year":"2008","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.bcp.2020.114057_b1285","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-319-08927-0_12","article-title":"Possible role of Resveratrol targeting Estradiol and Neprilysin pathways in Lipopolysaccharide model of Alzheimer disease","volume":"822","author":"El-Sayed","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bcp.2020.114057_b1290","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.yexcr.2015.04.004","article-title":"(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer\u2019s disease model mice by upregulating neprilysin expression","volume":"334","author":"Chang","year":"2015","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bcp.2020.114057_b1295","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3736\/jcim20100210","article-title":"Effects of Naoerkang on expressions of \u03b2-amyloid peptide 1\u201342 and neprilysin in hippocampus in a rat model of Alzheimer\u2019s disease","volume":"8","author":"Yuan","year":"2010","journal-title":"J. Chinese Integr. Med."},{"key":"10.1016\/j.bcp.2020.114057_b1300","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cyto.2018.12.008","article-title":"Decoding the enigma of antiviral crisis: does one target molecule regulate all?","volume":"115","author":"Mahmud-Al-Rafat","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.bcp.2020.114057_b1305","first-page":"121","article-title":"Severe acute respiratory syndrome: clinical and laboratory manifestations","volume":"25","author":"Lam","year":"2004","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.bcp.2020.114057_b1310","doi-asserted-by":"crossref","first-page":"9259646","DOI":"10.1155\/2016\/9259646","article-title":"Biologics for targeting inflammatory cytokines, clinical uses, and limitations","volume":"2016","author":"Rider","year":"2016","journal-title":"Int. J. Cell Biol."},{"key":"10.1016\/j.bcp.2020.114057_b1315","first-page":"78","article-title":"Side effects of anticytokine strategies","volume":"63","author":"van der Meer","year":"2005","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.bcp.2020.114057_b1320","unstructured":"K. Frie, K. Gbinigie, Chloroquine and hydroxychloroquine: current evidence for their effectiveness in treating COVID-19, Cent. Evidence-Based Med. Nuff. Dep. Prim. Care Heal. Sci. Univ. Oxford--25 Maart. 2020 (2020)."},{"key":"10.1016\/j.bcp.2020.114057_b1325","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"2020","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents."},{"key":"10.1016\/j.bcp.2020.114057_b1330","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1574884711308020006","article-title":"The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice","volume":"8","author":"Maximov","year":"2013","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114057_b1335","unstructured":"B.J. Delgado, W. Lopez-Ojeda, Estrogen, in: StatPearls [Internet], 2019."},{"key":"10.1016\/j.bcp.2020.114057_b1340","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00467-013-2716-0","article-title":"Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases","volume":"29","author":"Nadeem","year":"2014","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.bcp.2020.114057_b1345","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1165\/rcmb.2012-0451OC","article-title":"Angiotensin-converting enzyme 2\/angiotensin-(1\u20137)\/Mas axis protects against lung fibrosis by inhibiting the MAPK\/NF-kappaB pathway","volume":"50","author":"Meng","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.bcp.2020.114057_b1350","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/hr.2011.150","article-title":"Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension","volume":"35","author":"Zhu","year":"2012","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.bcp.2020.114057_b1355","article-title":"Interaction between RAAS inhibitors and ACE2 in the context of COVID-19","volume":"1","author":"Mourad","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.bcp.2020.114057_b1360","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3748\/wjg.v11.i10.1540","article-title":"A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults","volume":"11","author":"Wang","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bcp.2020.114057_b1365","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.dld.2011.03.001","article-title":"Racecadotril for childhood gastroenteritis: an individual patient data meta-analysis","volume":"43","author":"Lehert","year":"2011","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.bcp.2020.114057_b1370","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1097\/MJT.0000000000000354","article-title":"Role of neprilysin inhibitors in heart failure","volume":"24","author":"Adum","year":"2015","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.bcp.2020.114057_b1375","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6032631","article-title":"LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model","volume":"2019","author":"Chang","year":"2019","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.bcp.2020.114057_b1380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-42113-0","article-title":"Angiotensin receptor neprilysin inhibitor attenuates myocardial remodeling and improves infarct perfusion in experimental heart failure","volume":"9","author":"Pfau","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2020.114057_b1385","doi-asserted-by":"crossref","unstructured":"L.M. Burrell, J. Droogh, O. Man In\u2019t Veld, M.D. Rockell, N.K. Farina, C.I. Johnston, Antihypertensive and antihypertrophic effects of omapatrilat in SHR, Am. J. Hypertens. 13 (2000) 1110\u20131116.","DOI":"10.1016\/S0895-7061(00)01185-7"},{"key":"10.1016\/j.bcp.2020.114057_b1390","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1161\/hy1201.096569","article-title":"Omapatrilat versus lisinopril","volume":"38","author":"Campese","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2020.114057_b1395","doi-asserted-by":"crossref","unstructured":"I. Rodriguez-Gomez, R. Wangensteen, N.M. Atucha, F. O\u2019valle, R.G. Del Moral, J. Garcia-Esta\u00f1, F. Vargas, A. Osuna, Effects of Omapatrilat on Blood Pressure and Renal Injury in L-NAME and L-NAME Plus DOCA-Treated Rats, Am. J. Hypertens. 16 (2003) 33\u201338.","DOI":"10.1016\/S0895-7061(02)03144-8"},{"key":"10.1016\/j.bcp.2020.114057_b1400","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.bcp.2020.114057_b1405","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0735-1097(17)34071-8","article-title":"Influence of Sacubtril\/Valsartan on glycemic control in patients with type 2 diabetes and heart failure with reduced ejection fraction","volume":"69","author":"Seferovic","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2020.114057_b1410","first-page":"1","article-title":"Angiotensin\u2013neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury","volume":"38","author":"Uijl","year":"2019","journal-title":"J. Hypertens."},{"key":"10.1016\/j.bcp.2020.114057_b1415","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.brainres.2013.05.045","article-title":"Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer\u2019s disease mice","volume":"1529","author":"Park","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2020.114057_b1420","doi-asserted-by":"crossref","unstructured":"S. Sturiale, G. Barbara, B. Qiu, M. Figini, P. Geppetti, N. Gerard, C. Gerard, E.F. Grady, N.W. Bunnett, S.M. Collins, Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11653\u201311658.","DOI":"10.1073\/pnas.96.20.11653"},{"key":"10.1016\/j.bcp.2020.114057_b1425","first-page":"1457","article-title":"Neutral endopeptidase (EC 3.4.24.11) downregulates the onset of intestinal inflammation in the nematode infected mouse","volume":"52","author":"Barbara","year":"2003","journal-title":"Inflamm. Inflamm. Bowel Dis."},{"key":"10.1016\/j.bcp.2020.114057_b1430","first-page":"2849","article-title":"Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo","volume":"4","author":"Bunn","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2020.114057_b1435","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1067\/msy.2002.125309","article-title":"Recombinant human neutral endopeptidase ameliorates pancreatic elastase-induced lung injury","volume":"132","author":"Lightner","year":"2002","journal-title":"Surgery."},{"key":"10.1016\/j.bcp.2020.114057_b1440","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1172\/JCI114236","article-title":"Recombinant human enkephalinase (neutral endopeptidase) prevents cough induced by tachykinins in awake guinea pigs","volume":"84","author":"Kohrogi","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2020.114057_b1445","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0014-2999(92)90419-5","article-title":"Tachykinin-induced dyspnea in conscious guinea pigs","volume":"210","author":"Kusner","year":"1992","journal-title":"Eur. J. Pharmacol."}],"updated-by":[{"DOI":"10.1016\/j.bcp.2020.114249","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000}}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220302914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220302914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:15:13Z","timestamp":1757769313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220302914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":289,"alternative-id":["S0006295220302914"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114057","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.bcp.2020.114249","asserted-by":"object"}]},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114057"}}